<?xml version="1.0" encoding="UTF-8"?>
<p class="p">CCl
 <sub xmlns="http://www.w3.org/1999/xhtml">4</sub> caused a marked disruption of oxidant/antioxidant balance in liver as indicated by the statistically significant elevation in MDA and NO levels to 236% and 407% in group 2 as compared to the control group (
 <xref ref-type="table" rid="tab3" class="xref">Table 3</xref>). Besides, there was a marked reduction in SOD and CAT antioxidant enzymes activities with a dramatic depletion in hepatic GSH content to 24.4%, 43.2%, and 23.4% of the control levels, respectively (
 <xref ref-type="table" rid="tab4" class="xref">Table 4</xref>). In the same line, TAC of the liver of CCl
 <sub xmlns="http://www.w3.org/1999/xhtml">4</sub>-intoxicated group showed a significant reduction to 39.7% (
 <xref ref-type="table" rid="tab4" class="xref">Table 4</xref>). Administration of MPOE concurrently with CCl
 <sub xmlns="http://www.w3.org/1999/xhtml">4</sub> for 6 weeks (group 3) showed a significant reduction of MDA and NO levels compared to those of group 2 (
 <xref ref-type="table" rid="tab3" class="xref">Table 3</xref>). MPOE partially restored SOD and CAT activities and GSH level (
 <xref ref-type="table" rid="tab4" class="xref">Table 4</xref>). Improvement of CCl
 <sub xmlns="http://www.w3.org/1999/xhtml">4</sub>-induced oxidative stress by MPOE was confirmed by the significant elevation of TAC, reaching 74% of the normal control level (
 <xref ref-type="table" rid="tab4" class="xref">Table 4</xref>). There were no significant differences in all measured oxidative stress markers or antioxidant parameters between groups 1 and 4 (Tables 
 <xref ref-type="table" rid="tab3" class="xref">3</xref> and 
 <xref ref-type="table" rid="tab4" class="xref">4</xref>).
</p>
